Study Title | APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors |
---|---|
Protocol ID | APG-115-US-002 |
Disease (Sub Disease) | Melanoma Solid tumours |
Diagnosis Stage | New Diagnosis Relapse/Refractory |
Sponsor | Ascentage Pharma Group Inc. |
Collaborators | Merck Sharp & Dohme Corp. |
Links | https://clinicaltrials.gov/ct2/show/NCT03611868 |
Trial Status | Closed to Recruitment |
Trial Open Date | 29/08/2018 |
Study Type | Treatment |
Phase | Phase 1/2 |
Age Eligibility | 12 Years and older |
International registry ID's | NCT03611868 |